Voyager Therapeutics (NASDAQ:VYGR) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Wednesday morning,Benzinga reports.

VYGR has been the subject of several other research reports. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price target (down previously from $11.00) on shares of Voyager Therapeutics in a research report on Tuesday, February 11th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Citigroup assumed coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Voyager Therapeutics has an average rating of “Buy” and a consensus price target of $15.08.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $4.06 on Wednesday. The company has a market capitalization of $221.78 million, a P/E ratio of 5.72 and a beta of 0.99. The company’s 50-day simple moving average is $4.95 and its two-hundred day simple moving average is $5.87. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million during the quarter, compared to analysts’ expectations of $16.58 million. During the same period in the previous year, the company posted $1.25 EPS. On average, research analysts expect that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after purchasing an additional 6,740 shares in the last quarter. FMR LLC increased its stake in Voyager Therapeutics by 26.9% during the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares in the last quarter. Barclays PLC increased its stake in Voyager Therapeutics by 55.8% during the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after purchasing an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after purchasing an additional 7,573 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in Voyager Therapeutics during the 3rd quarter valued at approximately $216,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.